Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $23.9 million.

  • Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) rose 27.08% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 28.68%. This contributed to the annual value of $23.9 million for FY2025, which is 28.68% up from last year.
  • Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) amounted to $23.9 million in FY2025, which was up 28.68% from $18.6 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $23.9 million in FY2025 and a low of $8.3 million during FY2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $18.6 million (2024), whereas its average is $18.3 million.
  • Data for Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY soared of 48.84% (in 2024) over the last 5 years.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $8.3 million in 2021, then grew by 26.06% to $10.4 million in 2022, then grew by 19.88% to $12.5 million in 2023, then soared by 48.84% to $18.6 million in 2024, then rose by 28.68% to $23.9 million in 2025.